Oppenheimer analyst Hartaj Singh maintained a Buy rating on Moderna (NASDAQ:MRNA) on Sunday, setting a price target of 178,... By Rajesh Kumar Singh and Carl O'Donnell (Reuters) - An advisory ...

Financial giants have made a conspicuous bullish move on Moderna. Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 17 unusual trades. Delving into the details, we found 47% of ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00. In the following chart, we are able to follow the development of ...

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

Shares of Moderna gained after a couple of SEC filings showed that two board members bought shares on the open market. Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock ...

Today, we are looking at therapeutics stocks, starting with Myriad Genetics (NASDAQ:MYGN). Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from ...

Leaving Copenhagen’s castle-like station, the train (5.3 hours, from 35 euros) traversed the five-mile bridge connecting ...

March 5, 2025 Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...